Patients Rare diseases, real opportunity: Why the UK’s next challenge... The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Patients Maintenance: The underexamined half of the GLP-1 story GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
Patients Why patient safety doesn't end at approval Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.
Patients Redefining the self-care pathway in the evolving hayfever la... When it comes to hayfever, proactive approach improves patient health literacy and empowers individuals to put their health back in their own hands.
Patients Specialty medication access hinges on a 48-hour window The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.
Patients Decline in overdose deaths ≠ The end of the opioid crisis Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to
News Click claims FDA okay for first-in-class schizophrenia DTx Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.